Skip to main content

Cancer screening evidence

Multi-cancer blood tests and the NHS-Galleri results

Galleri looks for cancer-associated signals in blood. In the NHS-Galleri trial, adding the test to usual care did not significantly reduce stage III and IV diagnoses combined, the main outcome. Stage IV alone was lower in a secondary analysis. The benefit for cancer deaths remains unproven.

Published by LongevityMate Editorial Team · Updated 2026-11-11 · 5 minute read

NHS-Galleri results

What the trial found

The 2026 NHS-Galleri trial found no significant reduction in stage III and IV cancer diagnoses combined, its main outcome. Stage IV diagnoses alone were lower in a secondary analysis, with uncertainty around the size of the difference. Fewer cancer deaths have yet to be demonstrated. Continue guideline-recommended screening and seek clinical assessment for symptoms regardless of the blood test result.See reference 1,See reference 3,See reference 4

Cancer screening consultation reviewing a multi-cancer blood test pathway and standard screening schedule
On this page

What a multi-cancer blood test measures

Multi-cancer early detection tests look for signals associated with several cancers in a blood sample. Galleri looks for patterns on fragments of DNA circulating in the blood. If it finds a signal, it predicts where the signal may have come from so clinicians can plan follow-up.See reference 2,See reference 3,See reference 4

A diagnosis requires further evaluation. The ability to detect a signal varies by cancer type and stage, and some cancers produce too little detectable signal to be picked up.See reference 2,See reference 3,See reference 4

What changed after the NHS-Galleri trial

Researchers randomly assigned 142,250 adults aged 50–77 in England to usual care with or without a multi-cancer blood test. They assessed three annual screening rounds. The main analysis counted stage III or IV diagnoses across 12 cancer types selected before the study.See reference 1,See reference 2

The combined diagnosis rate was similar between groups. The estimated rate ratio was 1.03, with a 95% confidence interval of 0.92–1.14. For stage IV alone, a secondary outcome, the estimated rate ratio was 0.86, with a 95% confidence interval of 0.74–1.00. That estimate is compatible with a lower stage IV rate and with little difference at the upper end of the interval.See reference 1

The result applies to this test, the cancers analysed and the population studied. Finding more cancers at an earlier stage does not by itself show that people live longer. The study was funded by GRAIL, which makes Galleri.See reference 1,See reference 3

What positive and negative results can mean

Result
Cancer signal detected
In the trial
Across the three rounds, 45.8% to 58.0% of people with a positive result were diagnosed with cancer.
What follows
A clinician can assess the signal and consider the appropriate imaging, tests or biopsy.See reference 2,See reference 3,See reference 4
Result
No cancer signal detected
In the trial
The test detected about 27% to 37% of cancers diagnosed within the study’s assessment window, depending on the round.
What follows
Continue established screening. Symptoms still need assessment, even after a negative result.See reference 2,See reference 3,See reference 4

Follow-up can carry risks and costs

A false positive can lead to additional appointments, imaging, biopsy, anxiety or cost. A negative result can give false reassurance. Before considering testing, discuss who would interpret the result, who would coordinate follow-up and what expenses might be involved. Follow the screening guidance for your age, risk and location.See reference 3,See reference 4

Galleri’s US regulatory status

In September 2026, an FDA advisory panel voted in favour of the benefit–risk balance for the proposed use. The panel also raised questions about how the label should describe early detection and the need for further study.See reference 4

As of 11 November 2026, Galleri remained under FDA review. An advisory vote is a recommendation to the agency. Eligibility, availability and coverage can differ by country and health system.See reference 4,See reference 5

Common questions

Does a positive Galleri result confirm cancer?

A positive result indicates a cancer-associated signal. A clinician needs to confirm whether cancer is present and determine its type.See reference 2,See reference 3,See reference 4

Can a negative result replace a mammogram, bowel screening or another scheduled test?

Keep the established screening recommended for you. Multi-cancer blood tests can miss cancer, and the results do not replace follow-up for symptoms.See reference 3,See reference 4

Did the NHS-Galleri trial show that people live longer?

The trial’s main measure was the number of stage III or IV diagnoses across selected cancer types. A reduction in cancer deaths has yet to be shown.See reference 1,See reference 3

Get the weekly longevity brief

The week's best longevity research in plain English. Free, every Tuesday.

References

  1. 1. Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

    The New England Journal of MedicineRandomized trial

  2. 2. Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial

    Nature MedicineRandomized trial

  3. 3. Questions and Answers about Multi-Cancer Detection Tests

    National Cancer InstituteOfficial guidance

  4. 4. Molecular and Clinical Genetics Panel Meeting Summary

    US Food and Drug AdministrationOfficial guidance

  5. 5. GRAIL Quarterly Report for the period ended September 30, 2026

    US Securities and Exchange CommissionEvidence review

Editorial transparency

Published by
LongevityMate Editorial Team
Published
Updated

Medical disclaimer

This guide provides general education. A clinician can help you interpret a result and choose screening based on your health, risk and local guidance.